Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab vs Chemotherapy in Metastatic Triple-Negative Breast Cancer (KEYNOTE-119)
NCT02555657Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Oct 2015
- Primary completion
- Apr 2019
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
01
Overview
Phase 3, randomised, open-label trial of pembrolizumab in triple-negative breast cancer (TNBC) (2 arms), sponsored by Merck & Co. Primary endpoint: Overall Survival at 36 months. Started Oct 2015; status: completed.
02
Drugs
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT02555657.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02555657.